Dr Vivek Naranbhai

Clinical Research Fellow

VivekNaranbhai

Vivek Naranbhai is a South African clinician-scientist and a Clinical Research Fellow at the Wellcome Trust Centre for Human Genetics, University of Oxford. He moved to Oxford in 2011 as a Rhodes Scholar to pursue a second PhD/DPhil in genetics of infectious disease in the laboratory of Adrian VS Hill, Helen McShane and Andrew Morris and in collaboration with the laboratory of Julian Knight.

Research Interest:

Vivek’s work spans immunology ,genetic epidemiology and bioinformatics in a range of infectious diseases chiefly HIV and tuberculosis-the worlds leading killers of adults and adolescents. He co-leads the International Tuberculosis Host Genetics Consortium, a global effort to understand how the genetic background of humans affects our risk of tuberculosis.

Awards and affiliations:

Vivek is a research associate and honorary senior lecturer at the Centre for the AIDS Programme of Research in South Africa (CAPRISA) University of KwaZulu Natal. Vivek obtained an MBChB, Honours in Medical Microbiology and his first PhD (Immunology) concurrently at the Nelson R Mandela School of Medicine, South Africa working on Natural Killer cell responses in HIV with Salim Abdool Karim, William Carr and Marcus Altfeld (Ragon Institute of MIT, Harvard and MGH). Vivek was the deputy-director of the Vaccine and Pathogenesis Programme at CAPRISA where he was involved in studies of Tenofovir gel for preventing HIV acquisition in women. He was a Fogarty-Ellison Research Fellow (2007), is a recipient of the Pfizer Young Scientists award-South Africa (2008) and was one of the 100 brightest young minds-South Africa (2009). He was elected as a young scientist representative for South Africa to the World Economic Forum ‘Summer Davos’ in 2011, in 2013 was recognised as one of the top 200 Young South Africans shaping the country’s future by the Mail and Guardian and in 2015 was selected to attend the Lindau Nobel lectures.

Key Publications:

  1. Naranbhai V, Fairfax BP, Makino S, Humburg P, Wong D, Ng E, Hill AVS, Knight JC. Genomic modulators of gene expression in human neutrophils. Nature Communications. 2015 Jul 7;6:7545. doi: 10.1038/ncomms8545.
  2. Naranbhai V, Fletcher HA, Tanner R, O’Shea M, McShane H, Fairfax BP, Knight JC, Hill AVS. Distinct transcriptional and anti-mycobacterial profiles of peripheral blood monocytes dependent on the ratio of monocytes:lymphocytes. EBiomedicine. 2015 Sep 24;2(11):1619-1626. eCollection 2015 Nov.
  3. Naranbhai V, Hill AVS, Abdool Karim SS, Naidoo K, Abdool Karim Q, Warimwe G,  McShane H, Fletcher H. Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among adults initiating antiretroviral therapy. J Infect Dis. 2014 Feb;209(4):500-9.
  4. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, Abdool Karim Q, Carr WH and the CAPRISA004 TRAPS team. Innate Immune activation enhances HIV-1 acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis. 2012 Oct 1;206(7):993-1001.  

Click here for all publications and here for Vivek’s profile.

 

Vivek Naranbhai, MBChB, BSc.MedSci.Hons(Med Micro), PhD

Clinical Research Fellow, Wellcome Trust Centre for Human Genetics, University of Oxford

Co-lead: International Tuberculosis Host Genetics Consortium

Research Associate: Centre for the AIDS Programme of Research in South Africa

Honorary Senior Lecturer: School of Laboratory Medicine and Medical Sciences, UKZN

vivek.naranbhai@ndm.ox.ac.uk